Back to top
more

Ono Pharmaceutical Co. (OPHLF)

(Delayed Data from OTC)

$15.96 USD

15.96
900

-0.12 (-0.75%)

Updated Apr 9, 2024 09:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why

by Zacks Equity Research

Ono Pharmaceutical Co. (OPHLF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Sell Stocks for June 2nd

by Zacks Equity Research

OPHLF, TOELY and TLYS have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2023.

3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth Stock

by Zacks Equity Research

Ono Pharmaceutical Co. (OPHLF) possesses solid growth attributes, which could help it handily outperform the market.

Ono Pharmaceutical Co. (OPHLF) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Ono Pharmaceutical Co. (OPHLF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Acadia Healthcare (ACHC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acadia Healthcare (ACHC) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.

Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Homology Medicines (FIXX) and Ono Pharmaceutical Co. (OPHLF) have performed compared to their sector so far this year.

Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

by Zacks Equity Research

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys

by Zacks Equity Research

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark

by Zacks Equity Research

Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

by Zacks Equity Research

CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

Amgen: Phase III Data on Hyperparathyroidism Drug Published

by Zacks Equity Research

Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).